Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents: Proceedings of the Ninth Annual Symposium on New Drugs & Devices, October 27 & 28, 1988 - Developments in Cardiovascular Medicine 100 (Paperback)
  • Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents: Proceedings of the Ninth Annual Symposium on New Drugs & Devices, October 27 & 28, 1988 - Developments in Cardiovascular Medicine 100 (Paperback)
zoom

Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents: Proceedings of the Ninth Annual Symposium on New Drugs & Devices, October 27 & 28, 1988 - Developments in Cardiovascular Medicine 100 (Paperback)

(editor), (editor)
£149.99
Paperback 298 Pages / Published: 10/10/2011
  • We can order this

Usually dispatched within 3 weeks

  • This item has been added to your basket
The Symposium on New Drugs provides a forum for academic investigators, research and development personnel from the pharmaceutical industry and members of the Food and Drug Administration to discuss important clinical research issues. The Ninth Annual symposium on New Drugs addressed the problem of determining the risk versus benefit for use of three important classes of cardiovascular agents: thrombolytic, antiarrhythmic, and hypolipidemic agents. The use of thrombolytic agents has become one of the major advances in clinical intensive cardiologic care in the 1980s. While the lysis of clot(s) obstructing a major coronary artery should reverse or prevent the damage of acute myocardial ischemia and infarction, one must carefully consider the potential risks of such agents in regards to their potential benefits. The time when a thrombolytic agent should be administered to maximize benefit as well as how one defines a dose response relationship using intravenous critical care medicines were discussed as important clinical trial issues. The benefit versus risk data on currently available thrombolytic agents was reviewed and the potential roles for adjunctive agents addressed. Overall strategies regarding post- x thrombolytic care and relationships to sudden cardiac death were also detailed. The panel discussion sections provided a comprehensive view of the current thinking of the various participating groups in this symposium. Sudden cardiac death remains the number one cause of mortality in western industrialized societies.

Publisher: Springer-Verlag New York Inc.
ISBN: 9781461288886
Number of pages: 298
Weight: 492 g
Dimensions: 235 x 155 x 17 mm
Edition: Softcover reprint of the original 1st ed. 198

You may also be interested in...

Oxford Handbook of Cardiology
Added to basket
£34.99
Part-work (fascículo)
Making Sense of Echocardiography
Added to basket
Schaum's Outline of ECG Interpretation
Added to basket
The Dash Diet Action Plan
Added to basket
DASH Diet For Dummies
Added to basket
ECG Pocketcard
Added to basket
Bbp
£2.49
Cards
Blood Chemistry and CBC Analysis
Added to basket
Heart Disease
Added to basket
£9.99
Paperback
Rapid Interpretation of EKG's
Added to basket
The Healthy Heart Book
Added to basket
Cardiovascular Physiology 8/E
Added to basket
The HeartMath Solution
Added to basket

Please sign in to write a review

Your review has been submitted successfully.